Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Daflon 500 mg on progression of chronic venous disease after ASVAL surgery
2010-021270-11Phase 2Completed
- Sponsor
- Servier
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of micronized purified flavonoid fraction in chronic venous disease (CVD), venous stasis and Varicose Veins, sponsored by Servier. Primary endpoints: Efficacy of Daflon 500 mg on progression of chronic venous disease and Efficacy of Daflon 500 mg on venous symptoms. Started Sep 2010; status: completed.
02
Drugs
micronized purified flavonoid fraction
03
Conditions
chronic venous disease (CVD)venous stasisVaricose Veins
Beyond the preview
Go deeper on 2010-021270-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021270-11.